Basic and clinical studies on T-3262 in urinary tract infections

Abstract

T-3262, a new quinolone analogue, has been developed at the Toyama Chemical Co., Ltd. in Japan. We investigated the antimicrobial activity and clinical efficacy of the drug. 1) Antimicrobial activity was measured by the micro agar well method with an inoculum size of 106/ml. Antimicrobial activity of T-3262 was tested against 291 strains isolated from patients with urinary tract infections, and compared with those of ofloxacin (OFLX) and ciprofloxacin (CPFX). Bacterial strains consisted of 30 strains each of Staphylococcus spp., Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa and 21 strains of Citrobacter freundii. Antibacterial activity of T-3262 against Staphylococcus spp., E. faecalis and K. pneumoniae was stronger than those of the other two agents. Against E. coli, E. cloacae and P. aeruginosa, it was similar to CPFX, and superior to OFLX. However, against other Gram-negative bacilli, it was similar or superior to OFLX, but inferior to CPFX. 2) T-3262 was given at 150-600 mg per day for 3-15 days to 14 cases of acute uncomplicated cystitis, 24 of chronic complicated UTI and 1 of gonorrheal urethritis. According to the criteria proposed by the Japanese UTI Committee, the clinical efficacy in 9 cases of acute uncomplicated cystitis was excellent in 5 and moderate in 4, with an overall efficacy rate of 100%. Of 19 cases of chronic complicated UTI, 10 were excellent, 6 moderate and 3 poor, with an overall efficacy rate in chronic complicated UTI of 84.2%. One case of gonorrheal urethritis was moderate by the doctor's evaluation. As abnormal laboratory findings, transient elevation of GOT and GPT in one case, and eosinophilia in another were observed. Abnormal laboratory data in these cases returned to normal after treatment. No other subjective side effects were noted. © 1988, Japanese Society of Chemotherapy. All rights reserved.